News & Events

Theravance Biopharma announces opening of company’s new corporate office in Dublin, Ireland

Company Plans to Add 30 Highly Skilled Jobs in Dublin over Next Two Years

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today announced the opening of a new corporate office in Dublin, further establishing the Company’s presence in Ireland. The Company plans to expand its Dublin employee base by hiring 30 highly-skilled professionals over the next two years in in areas such as clinical development, finance, and technical operations.

An Tánaiste and Minister for Business, Enterprise and Innovation Frances Fitzgerald TD and other IDA Ireland executives joined members of the Theravance Biopharma board of directors and employees at the opening ceremony.

“The opening of our new office in Dublin demonstrates the increasingly important role that Theravance Biopharma plays in the global biopharmaceutical business, as we work with purpose to translate our science into therapeutics that can help patients around the world,” said Rick E Winningham, Chairman and Chief Executive Officer.

Commented Dr. Ann Brady, President, Theravance Biopharma Ireland, “This important expansion within Ireland provides an opportunity to tap into the extensive biopharmaceutical talent pool within the country. Our Irish team looks forward to helping to build on Theravance Biopharma’s legacy of scientific expertise, advance our pipeline of potential therapies in multiple disease areas, and ultimately change the way serious diseases are treated.”

"The pharmaceutical industry makes a huge contribution to the Irish economy in terms of jobs and manufacturing exports, and is one of our fastest growing sectors,” said An Tánaiste, Frances Fitzgerald. “My department through IDA Ireland is keen to attract new dynamic pharmaceutical companies like Theravance Biopharma who will broaden the reach of the industry here and generate new opportunities. I look forward to a mutually beneficial partnership developing."

“Theravance Biopharma is a very welcome addition to the biopharmaceutical operations in Ireland who have established highly specialized technical, financial and commercial operations throughout the country,” said Mary Buckley, Executive Director, IDA Ireland. “IDA Ireland looks forward to the Company’s further growth over the coming years.”

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.

Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult- to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist ("LAMA") being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease ("COPD"). Our neprilysin ("NEP") inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase ("JAK") inhibitors for the treatment of a range of inflammatory intestinal diseases.

In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including Trelegy Ellipta (the combination of fluticasone furoate, umeclidinium, and vilanterol in a single ELLIPTA® inhaler, previously referred to as the Closed Triple), currently approved in the US for the treatment of appropriate COPD patients and in development for the treatment of COPD in several other countries. The product is also currently in development for the treatment of asthma.For more information, please visit www.theravance.com.